Table 2 Side effects and reasons for ITF2357 cessation.
From: Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
Patient | Maximum ITF2357 dose (mg/day) | Duration of ITF2357 use (days) | Side effects | Response | Reason why ITF2357 was discontinued |
|---|---|---|---|---|---|
1 | 150 | 15 | Nausea, vomiting, diarrhea | Partial | Recurrence of attack and side effects (decreased CRP and leucocytes) |
2 | 150 | 90 | Abdominal pain, nausea | Partial | Complete course |
3 | 150 | 6 | Â | No | Aggravation of clinical symptoms (decreased CRP and leukocytes) |
4 | 100 | 3 | Â | No | More severe attack |
5 | 150 | 51 | Epigastric pain, nausea | Partial | Side effects |
6 | 100 | 57 | Â | No | Higher attack frequency and more severe attacks |
7 | 100 | 42 | Â | No | Higher attack frequency and more severe attacks |
8 | 150 | 90 | Â | Partial | Complete course |